We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Best Cheap Stocks Under $10 to Buy in December and 2026
Read MoreHide Full Article
Key Takeaways
How to find the best cheap stocks on Wall Street to buy in December and in 2026.
Buy surging top-ranked $10 biotech stock FOLD before it breaks out?
The Fed is projected to cut interest rates again on Wednesday. On top of that, the earnings outlook for 2026 remains very strong. This backdrop should leave investors feeling bullish in December and ready to add to their portfolios now and in the early weeks of 2026.
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
Along with their cheap stock prices, the stocks we learn to search for earn strong Zacks Ranks, driven by improving earnings outlooks. Wall Street is also very high on these cheap stocks trading for under $10 a share to buy now.
Penny Stocks
One dollar or less used to be the common threshold for what we call “penny stocks.” Today, the SEC has expanded penny stocks to securities that trade for less than $5 a share. Many investors avoid these stocks because they are speculative in nature.
Meanwhile, penny stocks often trade infrequently and hold wide bid/ask spreads. These stocks also carry many other traits that, in many cases, cause excessive volatility. With that said, some penny stocks perform incredibly well, which helps them remain attractive.
How to Find the Best Stocks Under $10 to Buy Now
Moving on, let’s briefly discuss the next class of cheap stocks. Stocks that trade in the $5 to $10 range are generally less risky than their penny stock counterparts. Investors might be more likely to have heard of these companies or seen the tickers. They are, however, still inherently more speculative than many other higher-priced stocks.
Investors can obviously find winning stocks for under $10 if they are extremely selective. So today, we narrowed the list of thousands of these more speculative stocks down to a more manageable group of $10 and under stocks that might help boost your portfolio.
Screen Parameters
• Price less than or equal to $10
• Volume greater than or equal to 1,000,000
• Zacks Rank less than or equal to 2
(No Holds, Sells or Strong Sells.)
• Average Broker Rating less than or equal to 3.5
(Average Broker Rating of a Hold or Better.)
• # of Analysts in Rating greater than or equal to 2
(Minimum of at least two analysts covering the stock.)
• % Change F1 Earnings Estimate Revisions -- 12 Weeks greater than or equal to 0
(Preferably upward earnings estimate revisions, but definitely no downward revisions.)
Here is one stock out of the roughly 70 highly-ranked stocks trading under $10 a share that made it through the screen today…
Buy Surging Cheap Biotech Stock FOLD for Growth and Upside
Amicus Therapeutics (FOLD - Free Report) is a biotech company that develops and sells specialized medicines for people with rare diseases, such as Fabry disease (which affects the kidneys and heart) and Pompe disease (a muscle-weakening disorder).
Amicus posted 17% revenue growth in the third quarter and reached “the milestone of GAAP profitability.” The company boasted that it “served more patients than ever before, driven by new Galafold starts and growing adoption for Pombiliti + Opfolda.”
Image Source: Zacks Investment Research
Amicus Therapeutics is projected to grow its revenue by 19% in 2025 and 2026, reaching $745.4 million next year. Its bottom-line outlook is even stronger.
The biotech firm expected to expand its adjusted earnings by 50% in FY25 and 87% next year to $0.67 a share, up from $0.24 in 2024. FOLD’s positive earnings revisions earn the stock a Zacks Rank #1 (Strong Buy) right now.
Image Source: Zacks Investment Research
FOLD stock has climbed by more than 60% over the last six months, putting the stock on the verge of a potential breakout above a key technical range (see chart above).
The stock’s average Zacks price target offers 61% upside from Amicus Therapeutics’ current ~$9.90 a share. On top of that, ~82% of the 11 brokerage recommendations Zacks has for the stock are “Strong Buys.”
Get the rest of the stocks on this list and start looking for the newest companies that fit these criteria. It's easy to do. And it could help you find your next big winner. Start screening for these companies today with a free trial to the Research Wizard. You can do it.
Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Image: Bigstock
The Best Cheap Stocks Under $10 to Buy in December and 2026
Key Takeaways
The Fed is projected to cut interest rates again on Wednesday. On top of that, the earnings outlook for 2026 remains very strong. This backdrop should leave investors feeling bullish in December and ready to add to their portfolios now and in the early weeks of 2026.
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
Along with their cheap stock prices, the stocks we learn to search for earn strong Zacks Ranks, driven by improving earnings outlooks. Wall Street is also very high on these cheap stocks trading for under $10 a share to buy now.
Penny Stocks
One dollar or less used to be the common threshold for what we call “penny stocks.” Today, the SEC has expanded penny stocks to securities that trade for less than $5 a share. Many investors avoid these stocks because they are speculative in nature.
Meanwhile, penny stocks often trade infrequently and hold wide bid/ask spreads. These stocks also carry many other traits that, in many cases, cause excessive volatility. With that said, some penny stocks perform incredibly well, which helps them remain attractive.
How to Find the Best Stocks Under $10 to Buy Now
Moving on, let’s briefly discuss the next class of cheap stocks. Stocks that trade in the $5 to $10 range are generally less risky than their penny stock counterparts. Investors might be more likely to have heard of these companies or seen the tickers. They are, however, still inherently more speculative than many other higher-priced stocks.
Investors can obviously find winning stocks for under $10 if they are extremely selective. So today, we narrowed the list of thousands of these more speculative stocks down to a more manageable group of $10 and under stocks that might help boost your portfolio.
Screen Parameters
• Price less than or equal to $10
• Volume greater than or equal to 1,000,000
• Zacks Rank less than or equal to 2
(No Holds, Sells or Strong Sells.)
• Average Broker Rating less than or equal to 3.5
(Average Broker Rating of a Hold or Better.)
• # of Analysts in Rating greater than or equal to 2
(Minimum of at least two analysts covering the stock.)
• % Change F1 Earnings Estimate Revisions -- 12 Weeks greater than or equal to 0
(Preferably upward earnings estimate revisions, but definitely no downward revisions.)
Here is one stock out of the roughly 70 highly-ranked stocks trading under $10 a share that made it through the screen today…
Buy Surging Cheap Biotech Stock FOLD for Growth and Upside
Amicus Therapeutics (FOLD - Free Report) is a biotech company that develops and sells specialized medicines for people with rare diseases, such as Fabry disease (which affects the kidneys and heart) and Pompe disease (a muscle-weakening disorder).
Amicus posted 17% revenue growth in the third quarter and reached “the milestone of GAAP profitability.” The company boasted that it “served more patients than ever before, driven by new Galafold starts and growing adoption for Pombiliti + Opfolda.”
Image Source: Zacks Investment Research
Amicus Therapeutics is projected to grow its revenue by 19% in 2025 and 2026, reaching $745.4 million next year. Its bottom-line outlook is even stronger.
The biotech firm expected to expand its adjusted earnings by 50% in FY25 and 87% next year to $0.67 a share, up from $0.24 in 2024. FOLD’s positive earnings revisions earn the stock a Zacks Rank #1 (Strong Buy) right now.
Image Source: Zacks Investment Research
FOLD stock has climbed by more than 60% over the last six months, putting the stock on the verge of a potential breakout above a key technical range (see chart above).
The stock’s average Zacks price target offers 61% upside from Amicus Therapeutics’ current ~$9.90 a share. On top of that, ~82% of the 11 brokerage recommendations Zacks has for the stock are “Strong Buys.”
Get the rest of the stocks on this list and start looking for the newest companies that fit these criteria. It's easy to do. And it could help you find your next big winner. Start screening for these companies today with a free trial to the Research Wizard. You can do it.
Click here to sign up for a free trial to the Research Wizard today.
Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks’ portfolios and strategies are available at: www.zacks.com/performance_disclosure